초록접수 현황
| 20F-181 | 구연 발표 |
Is adjuvant chemotherapy worthwhile after complete resection for single pulmonary metastasis from colorectal cancer?
Soyoung Lee, Sukki Cho, Beatrice Chia-Hui Shih, Wan Jin Hwang, Woohyun Jung, Yoohwa Hwang, Jae Hyun Jeon, Kwhanmien Kim, Sanghoon Jheon
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National University Hospital College of Medicine, Seoul, Republic of Korea
Purpose : Adjuvant chemotherapy (ACT) may reduce recurrence after pulmonary metastasectomy (PM) with an expectation of similar benefit of chemotherapy after the resection of liver metastasis from colorectal cancer (CRC). Few data suggest that there is a beneficial effect of ACT in single pulmonary metastasis after complete resection. This study is to investigate efficacy of ACT after PM for single pulmonary metastasis from CRC.
Methods : A retrospective study of patients who underwent PM for single pulmonary metastasis from January 2005 to December 2017 was performed. A Multivariable Cox proportional hazard regression model was used to identify the recurrence-free survival (RFS) after adjusting for potential confounders. The RFS was compared using the log-rank test between metastasectomy alone [ACT (-)] and metastasectomy followed by chemotherapy [ACT (+)] group.
Results : Of a total of 67 patients, 18 patients were ACT (-), and 49 patients were ACT (+) group. During median follow up of 49 months, recurrence occurred in 25 patients (37.3%). On univariable analysis, lymphatic invasion of primary tumor and high CEA before PM were significantly poor prognostic factors for RFS. Multivariable analysis showed that high CEA before PM was independent factor for RFS. In the ACT(-) and ACT (+) groups, the three years RFS were 72%% and 60%, respectively, the log-rank test did not show any difference between two groups (p=0.305).
Conclusion : Adjuvant chemotherapy after complete resection of single pulmonary metastasis from CRC did not show any benefit for recurrence-free survival. A large, prospective, well-designed randomized clinical trial is needed.
Methods : A retrospective study of patients who underwent PM for single pulmonary metastasis from January 2005 to December 2017 was performed. A Multivariable Cox proportional hazard regression model was used to identify the recurrence-free survival (RFS) after adjusting for potential confounders. The RFS was compared using the log-rank test between metastasectomy alone [ACT (-)] and metastasectomy followed by chemotherapy [ACT (+)] group.
Results : Of a total of 67 patients, 18 patients were ACT (-), and 49 patients were ACT (+) group. During median follow up of 49 months, recurrence occurred in 25 patients (37.3%). On univariable analysis, lymphatic invasion of primary tumor and high CEA before PM were significantly poor prognostic factors for RFS. Multivariable analysis showed that high CEA before PM was independent factor for RFS. In the ACT(-) and ACT (+) groups, the three years RFS were 72%% and 60%, respectively, the log-rank test did not show any difference between two groups (p=0.305).
Conclusion : Adjuvant chemotherapy after complete resection of single pulmonary metastasis from CRC did not show any benefit for recurrence-free survival. A large, prospective, well-designed randomized clinical trial is needed.
책임저자: Sukki Cho
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National University Hospital College of Medicine, Seoul, Republic of Korea
발표자: Soyoung Lee, E-mail : faustina117@gmail.com